Evoke Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Evoke Pharma
EVOK Stock  USD 29.70  0.60  2.06%   
Analyzing historical trends in various income statement and balance sheet accounts from Evoke Pharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Evoke Pharma's valuation are summarized below:
Gross Profit
14 M
Profit Margin
(0.36)
Market Capitalization
18.9 M
Enterprise Value Revenue
0.8654
Revenue
14.4 M
There are currently one hundred twenty fundamental signals for Evoke Pharma that can be evaluated and compared over time across rivals. We recommend to verify Evoke Pharma's prevailing fundamental drivers against the all of the trends between 2010 and 2026. The value of Market Cap is estimated to slide to about 9.2 M. Enterprise Value is expected to rise to about (17.1 K) this year

Evoke Pharma Total Revenue

12.38 Million

Check Evoke Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evoke Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.6 M, Interest Expense of 605.4 K or Selling General Administrative of 18.2 M, as well as many indicators such as Price To Sales Ratio of 0.9, Dividend Yield of 0.0 or PTB Ratio of 2.74. Evoke financial statements analysis is a perfect complement when working with Evoke Pharma Valuation or Volatility modules.
  
Build AI portfolio with Evoke Stock
Check out the analysis of Evoke Pharma Correlation against competitors.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.

Evoke Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10.7 M20.1 M9.9 M
Slightly volatile
Other Current Liabilities4 M3.8 M1.7 M
Slightly volatile
Total Current Liabilities12.5 M11.9 M4.1 M
Slightly volatile
Accounts Payable2.5 M2.3 M1 M
Slightly volatile
Cash9.5 M15.6 M8.7 M
Slightly volatile
Cash And Short Term Investments9.5 M15.6 M8.7 M
Slightly volatile
Common Stock Total Equity3.2 K3.1 K1.7 K
Slightly volatile
Common Stock Shares Outstanding2.3 M2.2 M464.9 K
Slightly volatile
Liabilities And Stockholders Equity10.7 M20.1 M9.9 M
Slightly volatile
Other Current Assets693.7 K892.2 K591.6 K
Slightly volatile
Other Stockholder Equity81.1 M156.2 M74.7 M
Slightly volatile
Total Liabilities6.7 M9.4 M8.9 M
Slightly volatile
Total Current Assets10.6 M19.8 M9.8 M
Slightly volatile
Common Stock163171768
Very volatile
Short and Long Term Debt Total4.8 M5.9 M3.3 M
Slightly volatile
Other Liabilities1.3 M1 M1.3 M
Very volatile
Non Current Assets Total339.4 K323.3 K232.2 K
Slightly volatile
Other Assets0.860.9145.9 K
Slightly volatile
Long Term Debt Total4.1 M5.8 M4.1 M
Slightly volatile
Capital Surpluse74.9 M110 M73.2 M
Slightly volatile
Short Term Debt6.1 M5.8 M1.7 M
Slightly volatile
Short and Long Term Debt6 M5.8 M1.9 M
Slightly volatile
Non Current Liabilities Other96.6 K101.7 K2 M
Slightly volatile
Net Invested Capital14.5 M13.8 M5.2 M
Slightly volatile
Net Working Capital6.3 M7.9 M5.9 M
Pretty Stable
Capital Stock1271341.5 K
Slightly volatile
Net Receivables2.9 M2.8 M586.8 K
Slightly volatile

Evoke Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization5.6 M6 M4.9 M
Slightly volatile
Selling General Administrative18.2 M17.3 M6.8 M
Slightly volatile
Other Operating Expenses10.2 M17.8 M9.4 M
Slightly volatile
Research Development14 K14.7 K3.1 M
Slightly volatile
Total Operating Expenses10.1 M17.4 M9.3 M
Slightly volatile
Interest Income333.9 K318 K197.9 K
Pretty Stable

Evoke Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.3 M889.1 K1.1 M
Slightly volatile
Begin Period Cash Flow8.8 M5.5 M7.6 M
Very volatile
End Period Cash Flow9.5 M15.6 M8.7 M
Slightly volatile
Change To Netincome1.6 M1.7 M1.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.90.941.9 K
Slightly volatile
Days Sales Outstanding14599.12271
Slightly volatile
Average Payables1.8 M1.7 M1.1 M
Slightly volatile
Stock Based Compensation To Revenue0.08240.086745.8977
Slightly volatile
Inventory Turnover1.020.920.6025
Slightly volatile
Days Of Inventory On Hand619524818
Slightly volatile
Payables Turnover0.250.20.1349
Slightly volatile
Average Inventory370.8 K417.1 K455.3 K
Slightly volatile
Research And Ddevelopement To Revenue0.00170.0018184
Slightly volatile
Capex To Revenue0.00.00.0
Slightly volatile
Cash Per Share7.88.21159
Slightly volatile
Days Payables Outstanding2.7 K2.4 K4.2 K
Slightly volatile
Income Quality0.991.170.9358
Pretty Stable
Current Ratio1.811.914.0305
Pretty Stable
Receivables Turnover3.583.812.3342
Slightly volatile
Capex Per Share0.00.00.0
Slightly volatile
Average Receivables298.8 K584.1 K189.9 K
Slightly volatile
Revenue Per Share6.544.843.1532
Slightly volatile
Interest Debt Per Share3.253.4237.6633
Slightly volatile
Debt To Assets0.320.341.7718
Slightly volatile
Operating Cycle7646231.1 K
Slightly volatile
Days Of Payables Outstanding2.7 K2.4 K4.2 K
Slightly volatile
Ebt Per Ebit0.820.931.0063
Slightly volatile
Effective Tax Rate6.0E-46.0E-49.0E-4
Slightly volatile
Quick Ratio1.771.863.9998
Slightly volatile
Cash Ratio1.431.513.6873
Slightly volatile
Days Of Inventory Outstanding619524818
Slightly volatile
Days Of Sales Outstanding14599.12271
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9824
Slightly volatile
Fixed Asset Turnover43.2659.8322.7917
Slightly volatile
Debt Ratio0.320.341.7718
Slightly volatile
Price Sales Ratio0.90.941.9 K
Slightly volatile
Asset Turnover0.270.530.1476
Slightly volatile

Evoke Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap9.2 M9.7 M22.6 M
Pretty Stable

Evoke Fundamental Market Drivers

Evoke Upcoming Events

19th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Evoke Pharma Financial Statements

Evoke Pharma investors utilize fundamental indicators, such as revenue or net income, to predict how Evoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-4.5 M-4.3 M
Total Revenue11.8 M12.4 M
Cost Of Revenue410 K430.5 K
Stock Based Compensation To Revenue 0.09  0.08 
Revenue Per Share 4.84  6.54 
Ebit Per Revenue(0.46)(0.48)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock:
How To Invest In Evoke
Details
Is Evoke Stock a good investment?
Details
What is Evoke Pharma's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Evoke Pharma Correlation against competitors.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. Projected growth potential of Evoke fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Evoke Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.38)
Revenue Per Share
5.182
Quarterly Revenue Growth
0.614
Return On Assets
(0.22)
Return On Equity
(1.35)
Investors evaluate Evoke Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Evoke Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Evoke Pharma's market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Evoke Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evoke Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Evoke Pharma's market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY